Introduction
============

Cervical cancer is one of the most common causes of cancer death in women worldwide [@B1]. Cervical intraepithelial neoplasia (CIN) is pre-invasive, preceding cervical cancer, and it is equivalent to the term cervical dysplasia. The concept of CIN was first introduced by Richart, who demonstrated that dysplasias have a high risk of progression to malignancy of the cervix [@B2]. The significant pathological features of CIN include immature cells, disorganization of the cells, abnormal nuclei, and increased mitotic activity [@B3]. Cervical lesions with mitoses and immature cells that are limited to the lower one-third of the epithelium are typically designated CIN 1, and involvement of the middle and upper one-third is diagnosed as CIN 2 and CIN 3, respectively [@B3]. Persistent infection with high-risk human papillomavirus (HR-HPV) is the single most important risk factor for the development of CIN [@B3]-[@B5]. HPV Type 16 is responsible for most HPV-caused diseases such as invasive cancer, CIN 2 and CIN 3 [@B4].

Evidence suggests a variety of high-risk factors for CIN recurrence, including positive surgical margins [@B6], [@B7], histologic CIN grade [@B8], pretreatment HR-HPV infection or persistent infection with HR-HPV following surgical resection [@B7], [@B9]-[@B11], glandular involvement [@B7], [@B12]- [@B14], and immunosuppression [@B13], [@B14]. Demographic factors such as age and menopausal status were also reported to be related to the recurrence of CIN to varying degrees [@B7], [@B11], [@B12]. CIN is a disease with a high potential for recurrence after surgery [@B7], and investigation of factors related to CIN recurrence is ongoing.

The causal relationship between inflammation and development of cancer has been well established [@B15]-[@B18]. In the tumor microenvironment, chronic inflammation contributes to promote tumor growth, tumor angiogenesis, invasion, metastasis, subversion of adaptive immune response, and reduced response to anticancer agents including hormones and chemotherapeutic agents [@B18], [@B19]. Chronic inflammation increases cancer risk, and although it is often undetectable, inflammation of any duration may have an essential role in carcinogenesis [@B18]. Recently, a number of studies investigated the most valuable measurement of the systemic inflammatory response and their potential use in clinical practice including cancer outcome prediction. Various easily measurable indices of blood that reflect the systemic inflammatory response have been recognized, including increased number of leukocytes, hypoalbuminemia, elevated C-reactive protein, and high cytokine levels [@B20]-[@B22].

Among these pretreatment blood parameters, the peripheral neutrophil-lymphocyte ratio (NLR), calculated as the absolute neutrophil count (ANC) divided by the absolute lymphocyte count (ALC), is regarded as a simple and effective marker of inflammation [@B23]-[@B25] that has been consistently reported to have an independent prognostic value in various tumors [@B21], [@B22], [@B26]. An increased NLR was associated with advanced stages of cervical neoplasia [@B27], [@B28], and patients with a higher histologic grade of CIN showed higher numbers of total leukocytes [@B29]. As far as we know, however, the prognostic value of the NLR for predicting CIN recurrence has not yet been reported. The aim of this study was to evaluate the prognostic significance of the NLR for recurrence in patients diagnosed with CIN of the uterus.

Materials and Methods
=====================

In this study, we retrospectively evaluated women diagnosed with CIN at different stages at two university hospitals. A total of 230 patients, aged 22 to 73 years, who underwent diagnostic excisional procedures for previous abnormal Papanicolaou smear results and were diagnosed with CIN were included in the study. Diagnostic excisional procedures such as conization or loop electrosurgical excision procedure (LEEP) with endocervical curettage (ECC) were performed by experienced gynecologists. Those who had received previous treatment for CIN, had evidence of infection including human immunodeficiency virus, or were using immunosuppressive drugs were excluded. This study was approved by the institutional review boards of both university hospitals for evaluation of patient data, and informed consent was waved considering the retrospective nature of data collection.

After a complete review of medical history, we collected information regarding patient demographics and clinicopathologic variables for analysis. The final cytological and pathological diagnosis of lesions followed the FIGO (International Federation of Gynecology and Obstetrics) classification, the histologic classification of which is based on the 2001 Bethesda System [@B30], and the classification of histological types was reviewed by a single expert pathologist for consistency. CIN recurrence was defined as histopathological CIN during follow-up. Hematology tests were performed in all participants prior to the operation as part of the routine work-up. Patients were excluded if their hematologic tests were not performed within two weeks before surgery.

Data from the entire cohort was used to choose optimal cutoff point of NLR for predicting recurrence based on receiver operating characteristic (ROC) curve analysis and determined that the optimal cutoff point of NLR for CIN recurrence was 2.1 (Fig. [1](#F1){ref-type="fig"}). We divided all patients into two groups depending on the cutoff value of NLR as follows: NLR-low (NLR≤ 2.1) and NLR-high (NLR\>2.1). Unpaired *t*-tests were applied for evaluation of continuous variables; independent-sample chi-squared tests were used for assessing categorical variables for comparison between the two groups.

In addition, we evaluated the impact of NLR inn recurrence-free survival (RFS). RFS was defined as the length of time between the date of excisional biopsy and the date of recurrence. Patients without documented disease recurrence were censored at the time of the last follow-up visit. RFS was analyzed using the Kaplan-Meier method; differences between survival curves were tested for statistical significance using log-rank tests. The univariate and multivariate Cox proportional hazards model was applied to identify the most significant independent prognosticator for RFS; variables with *P*-values of \< 0.1 on univariate analysis were included on multivariate analysis. All *P*-values are two-sided, and *P*-values of \< 0.05 were considered to be significant for statistical analyses. Data analysis was performed using IBM SPSS statistical software v. 18.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

The baseline characteristics of the patients are shown in Table [1](#T1){ref-type="table"}. Two hundred thirteen patients (92.6%) underwent conization, and 17 patients (7.4%) underwent LEEP with ECC. In total, 15 (6.5%), 43 (18.7%), and 172 patients (74.8%) were diagnosed with CIN I, CIN II, and CIN III, respectively. During the diagnostic excisional procedures, positive resection margins were reported in 34 patients (14.8%), and 28.7% of women in our cohort tested positive for HPV 16.

Table [2](#T2){ref-type="table"} shows the comparison of baseline characteristics between the two groups categorized according to the NLR cut-off values: NLR-low (n = 167, 72.6%) and NLR-high group (n = 62, 27.4%). Significant mean differences between the two groups were found in the following continuous variables: white blood cell count (WBC), absolute neutrophil count (ANC), absolute eosinophil count (AEC), absolute lymphocyte count (ALC), platelet-lymphocyte ratio (PLR), and lymphocyte-monocyte ratio (LMR). However there was no significant difference between the two groups for the categorical variables such as type of surgical treatment, histologic grade, rate of positive resection margins, or HPV 16 infection rate.

The RFS rates during the entire follow-up period were significantly lower in the NLR-high group compared to the NLR-low group (*P* = 0.0125) (Fig. [2](#F2){ref-type="fig"}). Regarding other hematological parameters (Fig. [3](#F3){ref-type="fig"}), the RFS rates were significantly higher in those groups with low-ANC (*P*= 0.0225), high-ALC (*P*= 0.0342), low-AEC (*P*= 0.0077), and high-hemoglobin level (*P*= 0.0167). Patients with higher mean corpuscular volume (MCV) showed a trend toward higher RFS rates, but the difference did not make a significant significance (*P*= 0.0674).

The outcomes of univariate analysis for RFS identified significant variables, which are shown in Table [3](#T3){ref-type="table"}. Age, ANC, AEC, ALC, hemoglobin level, and NLR were variables with significant differences on univariate analysis for RFS. Using the multivariate Cox proportional hazards model, we identified NLR (hazard ratio \[HR\], 7.66; 95% confidence interval \[CI\], 2.34-25.10; *P*= 0.001), AEC (HR, 6.91; 95% CI, 1.82-26.24; *P*= 0.005), hemoglobin level (HR, 0.21; 95% CI, 0.07-0.65; *P*= 0.007), and MCV (HR,0.27; 95% CI, 0.08-0.92; *P*= 0.037) as the strongest prognostic factors (Table [3](#T3){ref-type="table"}).

Discussion
==========

CIN or cervical dysplasia has a relatively high potential for recurrence after surgery [@B7]. Most cases of mild cervical dysplasia regress spontaneously to normal [@B31], whereas high-grade CIN is regarded as a lesion that can progress to invasive carcinoma if left untreated [@B3]. However, a variety of factors, except the histologic grade of CIN, have also been shown to be related to the recurrence of cervical dysplasia [@B6]-[@B14]; thus, further investigation of the parameters related to CIN recurrence is needed. Leukocytosis and neutrophilia are one of the most frequently encountered alterations in cancer patients [@B22], [@B27], and these findings correlate significantly with advanced disease and, consequently, with prognosis [@B22], [@B27], [@B28]. The NLR has been regarded as a non-invasive and cost-effective marker that reflects systemic inflammatory conditions [@B22], [@B26], [@B32], and many studies have reported its prognostic value in diverse cancers [@B21], [@B22], [@B33]-[@B35]. The current study is, as far as we known, the first report on the association between NLR and CIN recurrence, and we showed that NLR is an independent prognostic factor for disease recurrence after surgical resection in CIN patients. Since Virchow first described the relationship between chronic inflammation and cancer [@B36], the association has become more widely recognized [@B15], [@B16], [@B19]**.**Continuous cell proliferation in a millieu rich in inflammatory cells including neutrophils and macrophpages, cell growth factors, angiogenic and lymphangiogenic growth factors, stroma, and DNA-damage-promoting agents promotes the cancer development [@B15]. Following tumorigenesis, cancer cells produce different arrays of cytokines and chemokines that are mitogenic and/or chemoattractant for various cells, including granulocytes, mast cells, monocytes/macrophages, fibroblasts, and endothelial cells [@B15], [@B37]. Additionally, activation of fibroblasts and infiltrating inflammatory cells secrete proteolytic enzymes, cytokines, and chemokines, which are mitogenic for cancer cells, as well as endothelial cells involved in angiogenesis; these factors augment growth of cancer cell and enable metastatic spread [@B15]. Several types of infection are well known to potentiate cancer development and dissemination; for example, *Helicobacter pylori* infection is associated with gastric cancer and mucosa-associated lymphoid tissue lymphoma, Epstein-Barr virus infection potentiate development of various kinds of malignant lymphoma, and hepatitis B or C virus infection increases the risk of hepatoma [@B15], [@B18].

It is also well established that the systemic inflammatory response is associated with alterations in circulating WBCs like neutrophilia and lymphocytopenia. In the clinic, hematology tests including WBC level are routinely carried out prior to cancer treatment; hence, the tests may help estimate the severity of the inflammatory response in cancer patients. [@B18], [@B21], [@B23]. Neutrophilia may be related to an environment favorable for development and progression of tumors; conversely, lymphocytes exert antitumor effects by inhibiting cell proliferation and migration; hence, a higher NLR is indicative of advanced or aggressive tumor behavior and negative treatment outcomes [@B21], [@B26].

Uterine cervical cancer is one of the most common malignancies and leading cause of cancer death among women worldwide [@B1], and it is preceded by a pre-invasive step in which defective, impaired neutrophil migration could be an early event in tumor development [@B28]. Tavares-Murta BM et al. [@B27] conducted a study in a total of 315 patients to evaluate the peripheral blood WBC counts in uterine cervical cancer and CIN. Compared with CIN and early-stage cervical cancer, leukocytosis, neutrophilia, lymphopenia, and a NLR ≥ 5 were more frequently observed in advanced stage cervical cancer patients; moreover, neutrophilia was more frequent even in the early stage cervical cancer, when comparing with the CIN group.

Several studies demonstrated the prognostic value of the pretreatment NLR in cervical cancer [@B26], [@B32], [@B38]. In 235 patients who underwent definitive concurrent chemoradiation therapy (CCRT) for cervical cancer, the pretreatment NLR was associated with tumor size, lymph node metastasis, and response to therapy, and pretreatment NLR was found to independently predict survival outcomes [@B26]. Other studies also showed that a pretreatment NLR was a significant prognosticator for survival in patients with cervical cancer [@B32], [@B38]. Inflammatory components are critical in the development and progression of cervical cancer, like in other cancers, and the NLR is a feasible biomarker to predict patient outcomes and guide adjuvant therapy in cervical cancer [@B26].

Eosinophils are considered to be one of the first recruited effectors of the acute inflammatory response [@B15]. In the present study, AEC was significantly associated with CIN recurrence on multivariate analysis. In previous studies, the blood AEC level has been reported to be related to the stage of the cervical and rectal cancers. In a study by Dalai et al, the blood AEC level in patients with stages III and IV cervical cancer was higher when compared with that of stages I and II disease. In addition, AEC level before treatment was useful in predicting radiation response [@B39], [@B40], a finding that is partially consistent with our results that the high-AEC group had lower RFS. However, the clinical significance of AEC in CIN is not certain; as the value of AEC as a predictor for recurrence of CIN has not been reported, the result of current study needs validation in subsequent studies.

In this study, pretreatment hemoglobin level was identified as valuable prognostic factors for RFS. In previous studies on cervical cancer, low pretreatment hemoglobin level has been associated with increased risk of cervical cancer recurrence [@B41]-[@B43], and these findings are partially consistent with our own.

In current study, pretreatment MCV value was identified as valuable prognostic factors for RFS. As far as we know, the clinical significance of MCV in CIN has not been reported, and our results need validation in subsequent studies.

This study has some limitations; it was a retrospective observational study with a relatively small sample size. In addition, we were unable to adjust for some critical confounders such as systemic infection or inflammation; like other non-specific markers of inflammation, the NLR may have been affected by the presence of other systemic diseases [@B44]. Finally, although we evaluated the role of NLR considering other inflammatory indices like PLR and LMR, we could not evaluate the Glasgow Prognostic Score (GPS) [@B19] due to a lot of missing values in the blood chemistry data. If we had investigated the prognostic value of the NLR in combination with diverse prognostic markers of systemic inflammation including GPS, the clinical value NLR for predicting CIN recurrence could have been more precisely determined. Further research is necessary in this regard.

In conclusion, this study was the first attempt to evaluate the prognostic value of the NLR for predicting CIN recurrence, and we found that NLR is an independent prognostic factor for RFS after surgical excision of CIN. Additionally, we found that the AEC, hemoglobin level, and MCV were strongly associated with RFS, as determined by multivariate analysis using a Cox model. These hematological parameters might provide additional prognostic value beyond that offered by standard clinicopathologic parameters. Further large-scale trials are needed to clarify the preliminary findings of the present study.
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Cumulative recurrence-free survival according to hematologic parameters other than neutrophil-lymphocyte ratio.
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###### 

Clinicopathologic and laboratory parameters in patients with cervical intraepithelial neoplasia.

  Characteristics    Mean ± SD (N=230)   
  ------------------ ------------------- -------------
  Age                45.4 ± 10.6         
  Body mass index    22.5 ± 3.1          
  Treatment                              
                     Conization          213 (92.6%)
                     LEEP with ECC       17 (7.4%)
  Histology                              
                     CIN1                15 (6.5%)
                     CIN2                43 (18.7%)
                     CIN3                172 (74.8%)
  Resection margin                       
                     Negative            196 (85.2%)
                     Positive            34 (14.8%)
  Hemoglobin         13.4 ± 1.0          
  MCV                90.8 ± 6.2          
  Platelet           318.7 ± 67.3        
  WBC                6161.2 ± 1561.6     
  ANC                3601.6 ± 1308.4     
  AMC                386.8 ± 135.2       
  AEC                120.9 ± 100.3       
  ALC                2045.1 ± 560.7      
  NLR                1.9 ± 0.9           
  PLR                166.8 ± 57.3        
  LMR                5.8 ± 2.1           
  HPV16                                  
                     Negative            164 (71.3%)
                     Positive            66 (28.7%)

AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; CIN, cervical intraepithelial neoplasia; HPV, human papilloma virus; LMR, lymphocyte-monocyte ratio; MCV, mean corpuscular volume; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; WBC, white blood cell count.

###### 

Comparison of the clinical and laboratory parameters between two groups of patients with cervical intraepithelial neoplasia divided according to neutrophil-lymphocyte ratio.

                     NLR≤ 2.1(N=167)   NLR\>2.1(N=63)    *P*-value    
  ------------------ ----------------- ----------------- ------------ --
  Age                45.8 ± 10.4       44.3 ± 11.1       0.342^a^     
  Body mass index    22.7 ± 3.0        22.0 ± 3.2        0.155^a^     
  Treatment                                              1.000^b^     
                     Conization        155 (92.8%)       58 (92.1%)   
                     LEEP with ECC     12 (7.2%)         5 (7.9%)     
  Histology                                              0.995^b^     
                     CIN1              11 (6.6%)         4 (6.3%)     
                     CIN2              31 (18.6%)        12 (19.0%)   
                     CIN3              125 (74.9%)       47 (74.6%)   
  Resection margin                                       0.938^b^     
                     Negative          143 (85.6%)       53 (84.1%)   
                     Positive          24 (14.4%)        10 (15.9%)   
  Hemoglobin         13.4 ± 1.0        13.4 ± 1.1        0.983^a^     
  MCV                90.8 ± 6.6        90.6 ± 5.0        0.804^a^     
  Platelet           315.7 ± 69.7      326.8 ± 60.1      0.267^a^     
  WBC                5829.8 ± 1379.1   7039.8 ± 1683.4   0.000^a^     
  ANC                3130.4 ± 933.4    4850.5 ± 1344.4   0.000^a^     
  AMC                383.1 ± 124.8     396.8 ± 160.4     0.540^a^     
  AEC                130.8 ± 104.4     94.5 ± 83.5       0.007^a^     
  ALC                2182.9 ± 546.1    1679.8 ± 419.6    0.000^a^     
  PLR                152.6 ± 50.7      204.4 ± 57.1      0.000^a^     
  LMR                6.2 ± 2.2         4.7 ± 1.5         0.000^a^     
  HPV16                                                  0.850^b^     
                     Negative          118 (70.7%)       46 (73.0%)   
                     Positive          49 (29.3%)        17 (27.0%)   

^a^*P*-valuesbyunpaired *t*-test.

^b^*P*-valuesby chi-square test.

AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; CIN, cervical intraepithelial neoplasia; HPV, human papilloma virus; LMR, lymphocyte-monocyte ratio; MCV, mean corpuscular volume; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; WBC, white blood cell count.

###### 

Relationships between clinical and laboratory parameters and recurrence-free survival in patients with cervical intraepithelial neoplasia.

  Variable                                 Univariate                   Multivariate                       
  ---------------------------------------- -------------------- ------- -------------- ------------------- -------
  Age (years) (≤ 40 vs. \>40)              4.62 (1.03-20.65     0.045                                      
  Body mass index (≤23 vs. \>23)           2.62 (0.91-7.55)     0.075                                      
  ANC (per µL) (≤ 4192.5 vs. \>4192.5)     3.22 (1.12-9.27)     0.031                                      
  AEC (per µL) (≤ 92.2 vs. \>92.2)         4.80 (1.34, 17.20)   0.016                  6.91 (1.82-26.24)   0.005
  ALC (per µL) (≤ 1428.8 vs. \>1428.8)     0.31 (0.10-0.98)     0.045                                      
  Hemoglobin (g/dL) (≤ 13.1 vs. \> 13.1)   0.30 (0.11-0.86      0.024                  0.21 (0.07-0.65)    0.007
  MCV (fL) (≤ 90.7 vs. \> 90.7)            0.35 (0.11-1.13)     0.079                  0.27 (0.08-0.92)    0.037
  NLR (≤ 2.1 vs. \> 2.1)                   3.54 (1.23, 10.20)   0.019                  7.66 (2.34-25.10)   0.001

Hazard ratios were obtained using Cox\'s proportional hazard model.

AEC, absolute eosinophil count; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; MCV, mean corpuscular volume; NLR, neutrophil-lymphocyte ratio.

[^1]: \#Chun S and Shin K contributed equally to the study.

[^2]: \* Kim HY and Kim KH carry out equal roles as co-corresponding authors.

[^3]: Competing Interests: The authors have declared that no competing interests exist.
